The Cornell Board of Trustees and Weill Cornell Medicine Board of Fellows have approved the appointment of Dr. Francis Lee as interim dean of Weill Cornell Medicine and interim provost for medical affairs.
New research finds that cells are much more precise in how they ingest substances than previously thought, opening the door to potential treatments for several diseases.
A Cornell-led group of researchers has developed an online search method that employs natural language processing to identify terms that are semantically similar to those for cancer screening tests, but in colloquial language.
Five people who had life-altering, seemingly irreversible cognitive deficits following moderate to severe traumatic brain injuries showed substantial improvements in their cognition and quality of life after receiving an experimental form of deep brain stimulation in a phase 1 clinical trial.
A growing percentage of U.S. adults, even those who trust science, said harassing or threatening public health officials over COVID-19 business closures was justified, according to a new study of public opinion surveys conducted during two phases of the pandemic.
New research in biomechanics measures the impact of head-first, hand-first and feet-first diving and the likelihood of injury at different diving heights.
A study suggests boosting “naturally-produced” antibodies in mothers may enhance infants’ immunity against bacterial pathogens that cause infectious gastrointestinal diseases.
A diverse group of students and recent graduates representing Cornell’s four contract colleges has been selected to receive the 2023 State University of New York Chancellor’s Award for Student Excellence.
The study suggests that a unique set of regulatory networks controlled by neurons in the gut may be viable targets for future drug therapies to combat chronic inflammatory diseases including asthma, allergy and inflammatory bowel disease.
Genetically engineered immune cells successfully target the specific cancer cells that may be responsible for relapse of acute myeloid leukemia, according to a preclinical study by investigators at Weill Cornell Medicine.